New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company looks to refresh its portfolio amid looming patent losses and waning Covid vaccine sales. In FY25, Pfizer generated full-year revenues of $62.6bn. While this meets the company’s previously adjusted FY25 profit forecast of$62bn, it represents a 2% operational decline compared to FY24. Earnings per share (EPS) were in line with Citi analyst consensus, standing at $1.36, although they wer ...